

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 August 2024 (29.08.2024)



(10) International Publication Number
WO 2024/174020 A1

(51) International Patent Classification:

A61K 39/42 (2006.01) C07K 16/08 (2006.01)
A61P 31/22 (2006.01)

(21) International Application Number:

PCT/CA2024/050116

(22) International Filing Date:

31 January 2024 (31.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3190962 23 February 2023 (23.02.2023) CA

(71) Applicant: **XBIOTECH INC.** [CA/CA]; 1055 West Hastings Street, Suite 300, Vancouver, British Columbia V6E 2E9 (CA).

(72) Inventors: **SIMARD, John**; 5217 Winnebago Lane, Austin, Texas 78744 (US). **SHIVASWAMY, Sushma**; 5217 Winnebago Lane, Austin, Texas 78744 (US).

(74) Agent: **DAMIANI, Michael** et al.; Borden Ladner Gervais LLP, 100 Queen Street, Suite 1300, Ottawa, Ontario K1P 1J9 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: HERPES ZOSTER TREATMENT




FIG. 1

(57) Abstract: Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*